NEW YORK (GenomeWeb News) – French genome engineering company Cellectis said yesterday that it will collaborate with the French National Institute for Agricultural Research, or INRA, to investigate the use of Cellectis' technology in a range of applications.

Under the five-year, non-exclusive agreement, Cellectis and INRA will investigate the potential of a range of technologies in which Cellectis specializes, including reverse genetics, homologous recombination, and gene targeting, in applications such as cell biology and plant and animal biotechnology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.